Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 18/20 | 0.39 |
| ▸ | JAK2 | O60674 | 16/20 | 0.39 |
| ▸ | JAK1 | P23458 | 15/20 | 0.39 |
| ▸ | TYK2 | P29597 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22387906 | 0.82 | MEN1 (0.40) | JAK3JAK2JAK1TYK2MEN1 | |
| SCHEMBL28014875 | 0.75 | DPP4 (0.43) | JAK3JAK2JAK1TYK2MEN1 | |
| SCHEMBL18525632 | 0.72 | CHRM2 (0.44) | JAK3JAK2JAK1TYK2MEN1 | |
| SCHEMBL12957767 | 0.71 | ALDH1A1 (0.63) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20183292 | 0.71 | ALDH1A1 (0.42) | JAK3JAK2JAK1TYK2MEN1 | |
| SCHEMBL13724137 | 0.71 | JAK3 (0.44) | JAK3JAK2JAK1TYK2MEN1 | |
| SCHEMBL22620113 | 0.71 | JAK3 (0.44) | JAK3JAK2JAK1TYK2MEN1 | |
| SCHEMBL14426034 | 0.71 | ALDH1A1 (0.63) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL14644693 | 0.71 | ALDH1A1 (0.63) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL24300277 | 0.71 | JAK2 (0.35) | JAK3JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225493-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | JAK3 3725/4885JAK2 3226/4885JAK1 2914/4885 |
| US-11225493-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | JAK3 3725/4885JAK2 3226/4885JAK1 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.